Work

BRD4 inhibition sensitizes aggressive non-Hodgkin lymphomas to PI3Kδ inhibitors by suppressing PI3K reactivation and c-MYC expression.

Year: 2021

Type: article

Abstract: even after drug withdrawal. This study, thus, reveals the potential of simultaneously targeting PI3Kδ and BRD4 as a new therapeutic strategy for aggressive forms of NHL.

Source: PubMed

Authors: Weiqiong Zuo, Yongxia Zhu, Zhihao Liu, Yong Xia, Ying Xu, Cuiting Peng, Luoting Yu, Ningyu Wang

Institutions: Sichuan University, West China Medical Center of Sichuan University, West China Hospital of Sichuan University, State Key Laboratory of Biotherapy, University of Electronic Science and Technology of China, Sichuan Cancer Hospital, Southwest Jiaotong University

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W3127846301

FWCI: 0.21

Cites: 30

Cited by: 3

Related to: 10